echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > The CCR8-targeting monoclonal antibody CM369 jointly developed by Nuocheng Jianhua and Connoya has been approved for clinical use

    The CCR8-targeting monoclonal antibody CM369 jointly developed by Nuocheng Jianhua and Connoya has been approved for clinical use

    • Last Update: 2022-10-06
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    BEIJING, Aug.


    CM369, an anti-chemokine receptor 8 (CCR8) monoclonal antibody, is a potential first-in-class drug co-developed by Nuocheng Jianhua and Connoya, and will be developed as a monotherapy or in combination with other therapies for the treatment of high incidence advanced solid tumors, including lung cancer, gastrointestinal cancer,


    The specific mechanism of action of CCR8 makes it a potential tumor immune target


    Dr.


    "CCR8 is a specific target for Treg cells at tumor sites, and multiple preclinical studies of CM369 have demonstrated its durable efficacy and excellent safety profile," said Dr.


    InnoCare Forward-Looking Statements

    This press release contains the disclosure of certain forward-looking statements


    Source: Nuocheng Jianhua

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.